Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWAN: Individualized Faricimab Dosing in Diabetic Macular Edema
jRCTs031230213Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of faricimab in diabetic macular edema (DME), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in BCVA at 1 year. Started Aug 2023; status: active, not recruiting.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on jRCTs031230213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230213.